Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
Sponsor: Corestemchemon, Inc.
This PHASE1/PHASE2 trial investigates ALS and Amyotrophic Lateral Sclerosis and is currently completed. Corestemchemon, Inc. leads this study, which shows 11 recorded versions since 2011 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2023 — Aug 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Apr 2022 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE1_PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Feb 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Corestemchemon, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Seoul, South Korea